IL۱۷A and IL۱۷F Genetic Variations in Iranian Patients with Urothelial Bladder Cancer: A Case-Control Study

Publish Year: 1400
نوع سند: مقاله ژورنالی
زبان: English
View: 68

This Paper With 6 Page And PDF Format Ready To Download

  • Certificate
  • من نویسنده این مقاله هستم

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

JR_MISJ-12-3_007

تاریخ نمایه سازی: 25 آبان 1402

Abstract:

Background: Interleukin ۱۷ (IL۱۷) is a pro-inflammatory cytokine with pivotal modulatory effects on antitumor immune responses and has been reported to play a particularly important role in the occurrence and development of bladder cancer. We aimed to investigate the possible influence of IL۱۷ genetic variations on loci rs۲۲۷۷۵۹۱۳ and rs۷۶۳۷۸۰ with genetic susceptibility to bladder cancer in southern Iran. Method: In this case-control study, we enrolled ۱۸۰ patients with urothelial bladder cancer (mean age ۶۴ years) and ۱۸۰ age/gender matched healthy controls without any family history of cancer and autoimmune disorders. Genomic DNA was extracted from peripheral whole blood and genotyping was performed using PCR-RFLP method. Results: Genotype distributions in both the patients and controls were in agreement with Hardy-Weinberg equilibrium. The frequency of GG, GA, and AA genotypes for IL۱۷A were ۸۷ (۴۸.۳%), ۷۲ (۴۰%), and ۲۱ (۱۱.۷%) among patients; and ۹۲ (۵۱.۱%), ۷۵ (۴۱.۶%), and ۱۳ (۷.۳%) in the controls. The frequency of AA, AG, and GG genotypes for IL۱۷F in both the patients/controls were ۱۶۰ (۸۸.۹%)/ ۱۵۸ (۸۷.۸%), ۱۶ (۸.۹%)/ ۲۱ (۱۱.۷%), and ۴ (۲.۲%)/ ۱ (۰.۵%), respectively. Statistical analysis revealed no significant differences between the two groups regarding the frequency of genotypes and alleles (P>۰.۰۵). Conclusion: Our data collectively suggested that genetic variations on loci rs۲۲۷۷۵۹۱۳ and rs۷۶۳۷۸۰ of IL۱۷ genes were not associated with bladder cancer susceptibility in the Iranian population. Our finding has to be confirmed in different ethnic groups.

Authors

Arsalan Aslani

Department of Urology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

Mohammad Reza Haghshenas

Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

Nasrollah Erfani

Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

Abdol Aziz Khezri

Department of Urology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran